常茂生物(00954.HK)2020年純利下跌約71%至1682.7萬元 末期息0.02元
格隆匯 3 月 30日丨常茂生物(00954.HK)發佈截至2020年12月31日止全年業績公吿,集團銷售收入約為人民幣4.441億元,比去年同期的銷售收入下降約10%;歸屬於公司權益持有人的淨利潤約為人民幣1682.7萬元,同比下跌約71%;基本及攤薄每股利潤人民幣0.032元,擬派付末期現金股息每股人民幣0.02元(含税)。
2020年,新冠疫情在全球範圍內爆發並持續發酵,對集團外貿銷售及新業務拓展都帶來了不同程度的負面影響,銷售業績有所下滑。常州濱江開發區政府對位於長江沿岸一公里企業做出新的規劃調整,集團產品鏈的源頭順酐也在名單的列,順酐停產後主產品的原料需全部外購,而順酐市場在2020年下半年價格一路上漲,造成集團生產成本大幅增加;另外,從順酐生產副產蒸汽中獲得的效益也隨的消失,從而進一步增加了產品的生產成本,對全年業績造成了嚴重影響。全資子公司常茂生物連雲港有限公司於2020年未能順利復產,持續的經營虧損以及計劃搬遷化工裝置的非金融資產減值,同樣嚴重影響了集團2020年的業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.